Travere Therapeutics, Inc. (TVTX)
Travere Therapeutics, Inc. (TVTX) from its SEC filings: 2025 revenue $490.7 million (+110% vs the year before), net margin -5%, free cash flow $37.8 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $490.7 million |
| Revenue growth | +110% |
| Net income | -$25.5 million |
| Net margin | -5.2% |
| Free cash flow | $37.8 million |
| Diluted EPS | $-0.29 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +48% |
| Cash | $117.7 million |
| Long-term debt | $46.0 million |
| Share count, 1 year | +6% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.